The Food and Drug Administration is considering a recommendation for tailoring the COVID-19 vaccines for the 2024-2025 respiratory virus season to the JN.1 variant, according to Reuters. It’s been the dominant variant this year, and shots may target JN.1’s subvariants as well. The subvariant KP.2 was estimated to account for more than 28% of COVID-19 cases over a 2-week period in mid-May. Not unlike the annual flu vaccine, COVID vaccines are developed months in advance …
Read More